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patients(P: 0.37). Five relapses were observed in group A and
9 relapses occurred in group B (P: 0.23). The main causes of
death in both groups were relapse (50%) and aGvHD (22.2%).
The median follow-up time was 24 months. Diseaseefree
survival (DFS) was 47 in group A and 37 months (P: 0.34) in
groups B. The study showed overall survival (OS) of 45 and 34
months (P: 0.71) in groups A and B, respectively.
Conclusion: Even without considering the costs of treat-
ment, it is recommended that AML patients directly undergo
transplantation after being treated with a standard chemo-
therapy regimen (7+3) because no differences in DFS, OS,
GvHD were observed between the two groups.408
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Relapse is the most common cause of allogeneic stem cell
transplantation (SCT) failure. Non-cycling, chemoresistant
leukemic stem cells (LSCs) are thought to contribute to dis-
ease relapse and have been shown to be dependent on
signaling through the Hedgehog (Hh) pathway. Targeting
this pathway represents a rational approach to the eliminate
LSCs to prevent relapse. PF-04449913 (Pﬁzer) is a small
molecule inhibitor of the transmembrane G protein-coupled
Smoothened (SMO) receptor, a key mediator of the Hh
pathway. PF-04449913 demonstrates single-agent activity in
relapsed leukemias.
We designed an open label, Phase 2 study employing PF-
04449913 in acute leukemia andMDS patients following SCT.
Eligibility requirements include enrollment within 28-50
days of SCT, engraftment, and high risk of relapse. High
relapse risk is deﬁned for myeloablative conditioning regi-
mens in acute leukemia as the presence of persistent
morphologic disease or minimal residual disease (MRD) at
the time of transplant as measured by ﬂow cytometry, cy-
togenetics, or FISH, and, for MDS, persistent disease at the
time of transplant with poor risk cytogenetics. For non-
myeloablative transplants, patients with a relapse risk score
>0, as deﬁned by the Fred Hutchinson Cancer Research
Center scoring system, are also included. Patients receive
consecutive 28-day cycles of PF-04449913 at 100 mg/day for
up to one year or until toxicity or relapse. Twenty-eight pa-
tients are required for an 80% power to detect an estimatedFigure.one year relapse free survival improvement from a null hy-
pothesis of 30% to 53%.
To date 13 patients have enrolled including 9 AML, 3 ALL, and 1
MDS (7 myeloablative and 6 non-myeloablative). Median
follow up is 176 days. Three patients (one of whom relapsed)
required dose reductions to 50 mg due to muscle cramps and
dysgeusia, andonepatientdiscontinueddue tomuscle cramps.
No other signiﬁcant toxicities were attributed to the drug.
Three patients relapsed including one morphologic, one MRD,
and one with graft failure (developing prior to enrollment on
study)with subsequent relapse.Onepatient diedofGVHD, and
12 remain alive. One patient has completed the study and 7
remain on studywith amedianof 6 cycles completed (range 1-
10). Preliminary data suggests that PF-04449913 is well toler-
ated early post-SCT and may reduce relapse rates.409
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We recently found that early pre-emptiveDLI with
donor CD4+ T-Cells cultured in rapamycin (T-Rapa) allowed
allo-engraftment after low-intensity ﬂudarabine plus cyclo-
phosphamide (Cy) host conditioning (Blood, 2013). To eval-
uate further reductions in conditioning intensity, we
conducted a pilot clinical trial of allogeneic HSCT using a
novel regimen of pentostatin and low-dose, daily cyclo-
phosphamide (PC) in patients with refractory renal cell car-
cinoma (RCC, n¼10; Table 1). After PC conditioning, patients
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Rapa cells (schema, Fig. 1). PC conditioning resulted in pro-
found pre-transplant lymphopenia without a single episode
of ANC<1000 cells/ul (Fig. 2) and without any grade 3 or
greater toxicity. Donor T cell chimerismwas rapidly achievedand remained relatively mixed; in contrast, donor myeloid
cell chimerism was initially minimal (<1%) but gradually
established by day 100 post-HSCT (Fig. 2). There was no case
of classical acute GVHD (0/10); however, no clinical GVT ef-
fects were observed by RECIST criteria, thereby activating a
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S288protocol stopping rule. We conclude that the combination of
PC conditioning, high-dose sirolimus, and pre-emptive T-
Rapa DLI is a very safe method of achieving allo-engraftment
without substantial conditioning toxicity or acute GVHD.
However, this approach yielded split, mixed chimerism,
which was not conducive to GVT effects against refractory
RCC. The remarkable safety and minimal intensity of this
platform make it an attractive transplant approach for non-
malignant disorders but will require modiﬁcations aimed at
promoting GVT effects in malignant disorders.410
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Introduction: Although administration of G-CSF to healthy
donors for mobilization and collection of peripheral blood
stem cell (PBSC) is common in adult volunteers, there are
limited data on short-and especially long-term efﬁcacy in
healthy pediatric donors, notably due to ethical issues. The
purpose of this study was to assess the short- and long-
term adverse effects of using G-CSF in pediatric sibling
donors.
Methods: Healthy pediatric sibling (age15 years) donors of
PBSCwhose parents were reluctant to donate stem cells from
bone marrow (BMSC) were enrolled in this prospective
study. Written informed consent was obtained from all the
children’s parents before entering the transplantation pro-
gram. G-CSF (Neupogen, Roche, Switzerland) was admin-
istered at 5mg/kg once daily for 3 consecutive days and twice
on the fourth day. Questionnaires were used to assess the
health status of donors.
Results: 104 healthy pediatric donors of PBSCs aged 2.5-15
years (median age: 10 years) were followed for a median of
1527 days (393-4621 days). The most common short-term
side effects were headache (n¼4) and fatigue (n¼2). None of
the mentioned medical problems worsened after G-CSF in-
jection. Two pregnancies after the administration of G-CSF
resulted in normal births. No malignancy or death was
reported.
Discussion: To best of our knowledge, this is the ﬁrst
investigation on a large number of healthy pediatric donors
to assess long-term effects of PBSC donation. Our study in-
dicates PBSC collection, using G-CSF could be a safe and
effective method for healthy pediatric donors whose par-
ents are reluctant to allow their child to undergo collection
of bone marrow because of concerns over side effects of
anesthesia. Further studies with larger sample size are
required to determine the safety of using G-CSF in healthy
children.411
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tion of transplantation. In 1971, Fialkow reported the case of
a female patient with ALL who relapsed after a transplant
from her brother. Cytogenetics showed only donor derived
XY metaphases. Sporadic cases of DCL have since been re-
ported, however, the precise incidence remains unclear. An
EBMT review of 10489 allogeneic transplants found an inci-
dence ofw0.1%.
Case Report: A 41-year-old-man was admitted 567 days
after a double unrelated blood cord transplantation (UBCT)
for B-ALL. He received reduced-intensity conditioning
prior to his UBCT with cyclophosphamide 50 mg/kg, ﬂu-
darabine 200 mg/m2, and 200 cGy TBI (Cy/Flu/TBI). GVHD
prophylaxis included CSA and MMF. Post-transplant, bone
marrow (BM) and peripheral blood (PB) chimerism was
100% donor.
On day+515 post-transplant he was thrombocytopenic
with 8% blasts. A BM biopsy revealed a donor derived AML,
with 22% blasts. BM chimerism remained 100% donor. He
received decitabine at 20mg/m2 for 10 days. Post-treatment
BM biopsy was negative for AML.
On day+567, he was admitted with fever, pleuritic
chest pain and tachycardia. EKG demonstrated T-wave
inversions in V3-V5. Both troponin (1.8 ng/ml) and BNP
(805 pg/ml) were elevated. Chest CT revealed a circum-
ferential pericardial and nodular soft tissue densities
posterior to the heart and he ultimately underwent a
pericardectomy.
The pericardial pathology showed myeloid sarcoma. The
tumor cells were CD43+, MPO focal+, CD34 focal+, CD117
focal+, CD68weak+, CD163 focal+, PAX5-, CD56-, TdT-, CD79a
focal weak+ by immunohistochemistry. The chimerism
revealed that the lesion was entirely donor derived. A BM
biopsy showed no evidence of AML with normal hemato-
poiesis and full donor chimerism. Thus, cardiac myeloid
sarcoma represented an isolated site of disease.
Unfortunately, the patient continued to deteriorate and
expired on day+579.
Discussion:Within DCL, isolated donor derived granulocytic
sarcoma, as in our patient, is an extremely rare and chal-
lenging diagnosis. Reactive donor leukocytes can inﬁltrate a
host derived granulocytic sarcoma making it difﬁcult to
distinguish relapse from a DCL.
Given the comparatively recent introduction of UCBT,
fewer cases of cord blood associated DCL leukemia have
been reported in the literature when compared with PBSCT
or BMT. Some interesting trends have emerged. AML is the
most common type of UCBT DCL. There is a shorter interval
to the development of DCL in UCBT (median of 14.5
months) compared to BMT or PBSCT (36 months).
Abnormal karyotypes, particularly monosomy 7, are more
common in UCBT DCL. Perhaps, UCB is uniquely sensitive
to leukemogenic effects of conditioning. Given the pre-
dominance of AML DCL in UCBT, more cases of donor
myeloid sarcoma may emerge. Improved molecular testing
will allow precise detection and avoid mistakenly catego-
rizing DCL as relapsed disease.412
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